Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A Profit Margin

As of the most recent data (June 2026), FBIOP shows a profit margin of 155.13%. That compares with -28.5% in the prior-year period — up 644.2% year over year. That is above the Healthcare sector average of 19.13%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, FBIOP's profit margin is now 155.13% (was -28.5%) — a 644.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A is outperforming or lagging.

The Healthcare sector average profit margin is about 19.13%. Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A is at 155.13%, which is higher that average. That is roughly 710.9% above the sector mean. Use the comparison chart on this page to see how FBIOP stacks up against individual peers as well.

That compares with -28.5% in the prior-year period — up 644.2% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently 155.13%) with ownership activity and broader fundamentals.